Transurethral resection (TUR) is widely used to manage early-stage bladder cancer. A recent study has confirmed that a second, or restaging, TUR is associated with a lower risk of progression and cancer-related death. Restaging TUR is therefore recommended as a standard of care in patients with stage T1 bladder cancer.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Divrik, R. T., Sahin, A. F., Yildirim, U., Altok, M. & Zorlu, F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur. Urol. 58, 185–190 (2010).
Kulkarni, G. S. et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur. Urol. 57, 60–70 (2009).
Hall, M. C. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J. Urol. 178, 2314–2330 (2007).
Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 54, 303–314 (2008).
Brausi, M. et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur. Urol. 41, 523–531 (2002).
Dutta, S. C. et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J. Urol. 166, 490–493 (2001).
Herr, H. W., Donat, S. M. & Dalbagni, G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J. Urol. 177, 75–79 (2007).
Herr, H. W. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J. Urol. 174, 2134–2137 (2005).
Grimm, M. O. et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J. Urol. 170, 433–437 (2003).
Divrik, R. T., Yildirim, U., Zorlu, F. & Ozen, H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J. Urol. 175, 1641–1644 (2006).
The author declares no competing financial interests.
About this article
Cite this article
Dalbagni, G. Restaging TUR reduces recurrence and progression risk. Nat Rev Urol 7, 649–650 (2010). https://doi.org/10.1038/nrurol.2010.189
Preventive effect of pomegranate juice against chemically induced bladder cancer: An experimental study
Nature Reviews Urology (2019)
Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette–Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway
Biomedicine & Pharmacotherapy (2018)
Oncology Letters (2015)
A New Tool for Distinguishing Muscle Invasive and Non-Muscle Invasive Bladder Cancer: The Initial Application of Flexible Ultrasound Bronchoscope in Bladder Tumor Staging
PLoS ONE (2014)